期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 177, 期 2, 页码 221-225出版社
WILEY
DOI: 10.1111/bjh.14498
关键词
multiple myeloma; central nervous system relapse; clinical studies; marizomib
类别
资金
- Celgene Corporation
- Millenium (The Takeda Oncology Company)
Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifestation of extra-medullary disease with few therapeutic options, highlighting the unmet clinical need in these patients. Marizomib demonstrated encouraging activity in RRMM and has emerging clinical activity in glioma, making it a potential CNS-MM therapeutic intervention. Herein, we present two patients with RRMM and CNS involvement who benefited from marizomib-based therapy. Thesecases provide the first proof of principle for further exploring marizomib in CNS-MM patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据